EXEMESTANE (AROMASIN)

Course overview

Exemestane is U.S. FDA-approved in postmenopausal women as adjuvant treatment for estrogen-receptor positive early breast cancer (BC) after 2–3 years of tamoxifen, and to treat advanced BC that has progressed after tamoxifen therapy. This continuing education module is designed to give the reader/learner an increased understanding of exemestane. Readers may explore any or all of the topics. One contact hour of continuing education credit is available for those who successfully complete the post-test and evaluation form.